Overview

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2019-10-21
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fox Chase Cancer Center
Collaborator:
National Comprehensive Cancer Network
Treatments:
Vorinostat
Criteria
Inclusion Criteria:

- biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.

- FEV1 >/= 1 liter

- ECOG PS 0 or 1

- Able to swallow and absorb enterally

- Measurable disease per RECIST 1.1

- Adequate organ and marrow function including calculated creatinine clearance >/= 60
mL/min hepatic enzymes and alk phos
Exclusion Criteria:

- Chemotherapy or radiotherapy nitrosureas)

- Active bleeding

- Known brain mets

- Prior thoracic radiotherapy that would lead to overlap with current radiation field.

- More than 10% weight loss in 6 months.

- Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement

- Known HIV positive

- Prior treatment with an HDAC inhibitor